Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has developed into a global pandemic since its first outbreak in the winter of 2019. An extensive investigation of SARS-CoV-2 is critical for disease control. Various recombinant monoclonal antibodies of human origin that neutralize SARS-CoV-2 infection have been isolated from convalescent patients and will be applied as therapies and prophylaxis. However, the need for dedicated monoclonal antibodies in molecular pathology research is not fully addressed. Here, we produced mouse anti-SARS-CoV-2 spike monoclonal antibodies that exhibit not only robust performance in immunoassays including western blotting, ELISA, immunofluorescence, and immunoprecipitation, but also neutralizing activity against SARS-CoV-2 infection in vitro . Our monoclonal antibodies are of mouse origin, making them compatible with the experimental immunoassay setups commonly used in basic molecular biology research laboratories, and large-scale production and easy distribution are guaranteed by conventional mouse hybridoma technology.
Article activity feed
-
SciScore for 10.1101/2020.10.01.323220: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Sample collection is approved by Keio University Bioethics Committee with the number 20200063. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources For antibody production, monoclonal hybridomas were cultured in Hybridoma Serum-Free Medium (FUJIFILM Wako) supplemented with IL-6. IL-6suggested: NoneAfter three times washing in PBS-T (0. 1% Tween-20), the membrane was incubated in 1:5000 dilution of the peroxidase-conjugated sheep anti-mouse IgG secondary antibody (MP Biomedicals) for 30 min at room temperature. anti-mou…SciScore for 10.1101/2020.10.01.323220: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Sample collection is approved by Keio University Bioethics Committee with the number 20200063. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources For antibody production, monoclonal hybridomas were cultured in Hybridoma Serum-Free Medium (FUJIFILM Wako) supplemented with IL-6. IL-6suggested: NoneAfter three times washing in PBS-T (0. 1% Tween-20), the membrane was incubated in 1:5000 dilution of the peroxidase-conjugated sheep anti-mouse IgG secondary antibody (MP Biomedicals) for 30 min at room temperature. anti-mouse IgGsuggested: NoneMonoclonal antibodies starting from 100 µg/mL were four-folds serial diluted with blocking buffer to 12 gradients and incubated with plates for 1 hour at room temperature, followed by incubation with horseradish peroxidase (HRP) conjugated sheep anti-mouse secondary antibody (MP Biomedicals) 1:5000 diluted in blocking buffer for 30 min at room temperature. anti-mousesuggested: NoneACE2-binding inhibition assay: For spike pull-down assay, SΔTM glycoprotein was incubated with 1 µg anti-spike antibody in 50 µl binding buffer (PBS supplemented with 0.1% NP-40) at room temperature for 1 hour, then 3 µg of ACE2-SBP recombinant protein was applied the reaction for 1 hour. anti-spikesuggested: NoneAfter washing, beads were incubated with diluted antibodies for 20 min at 4°C, washed, incubated with 4 µg/mL of ACE2-FLAG for 20 min at 4°C, washed, and incubated with an anti-DYKDDDDK antibody conjugated with APC fluorophore (MBL) for 20 min at 4°C. anti-DYKDDDDKsuggested: NoneMouse anti-FLAG M2 antibody (Sigma) was also used as a control. anti-FLAGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Cell cultures: The mouse myeloma cell line SP2/0-Ag14 (RCB0209) was provided by the Riken Bioresouces Center (Tsukuba, Japan). SP2/0-Ag14suggested: RCB Cat# RCB0209, RRID:CVCL_2199)Splenocytes (1×108) were immediately mixed with 5×107 SP2/0 myeloma cells and fused using an electro cell fusion generator ECFG21 (NepaGene) according to the manufacturer’s instructions. SP2/0suggested: NoneLysates of 293T cells transfected with plasmids encoding full-length spike glycoproteins was also separated by SDS-PAGE for WB. 293Tsuggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)Immunoprecipitation of SΔTM was examined by SDS-PAGE followed by western blotting using antibody R52. Immunofluorescence: Before performing immunofluorescence, HeLa cells seeded on cover glasses were transfected with plasmids encoding full length SARS-CoV-2 spike protein for 2 days using Lipofectamine 2000 (Thermo Fisher). HeLasuggested: NoneVirus neutralization assay: SARS-CoV-2 virus (obtained from the National Institute of Infectious Diseases) was prepared from culture fluids harvested from infected VeroE6/TMPRSS2 cells (JCRB Cell Bank, JCRB1819) (Matsuyama et al., 2020). VeroE6/TMPRSS2suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Experimental Models: Organisms/Strains Sentences Resources Production of monoclonal antibodies: BALB/c mice were immunized twice in 3-week intervals, with the second immunization serving as a booster. BALB/csuggested: NoneSoftware and Algorithms Sentences Resources Signal was quantified by measuring absorbance at 450 nanometer using iMark Microplate Absorbance Reader (Bio-Rad Laboratories). Bio-Rad Laboratoriessuggested: (Bio-Rad Laboratories, RRID:SCR_008426)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
